glp-1 weight loss drug news today 2025 Pipeline Update: August - Prime Therapeutics Read the new article from

Compared to general practice, the more frequent and structured use of RDNs and MNT in these trials could be one reason why these trials demonstrated larger weight reductions than seen in real-world GLP-1 utilization for obesity

[DOI] [PMC free article] [PubMed] [Google Scholar] 15.Marso SP, Bain SC, Consoli A, et al

Teneligliptin, a DPP-4 inhibitor, demonstrated mild antinociceptive effects against heat-induced acute pain, but remarkable analgesic effects against partial sciatic nerve transection (PSNT)-induced neuropathic pain in rats [70]

Are GLP-1 agonists suitable for everyone

doi: 10.1007/s12325-017-0499-6 123 KalraSBhattacharyaSKapoorN

doi:10.1016/j.hjc.2018.11.008 31